CymaBay Therapeutics, Inc. — Revenue by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/13f7a586-1ef9-4cd4-9db1-a5957ab675f3/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $31.1M | 2023-01-01 – 2023-12-31 | evidence 0001193125-24-050758 |
| FY 2022 | $0 | 2022-01-01 – 2022-12-31 | evidence 0001193125-24-050758 |
| FY 2021 | $0 | 2021-01-01 – 2021-12-31 | evidence 0001193125-24-050758 |
| FY 2017 | $10.0M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-005435 |
| FY 2013 | $0 | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-124127 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CymaBay Therapeutics, Inc. — all facts · Net Income · Operating Income